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Abstract
Streptococcus agalactiae, also known as group B Streptococcus (GBS),
is the major cause of neonatal sepsis in humans. A critical step to
infection is adhesion of bacteria to epithelial surfaces. GBS adhesins
have been identified to bind extracellular matrix components and
cellular receptors. However, several putative adhesins have no
host binding partner characterised. We report here that surface-
expressed b protein of GBS binds to human CEACAM1 and CEACAM5
receptors. A crystal structure of the complex showed that an IgSF
domain in b represents a novel Ig-fold subtype called IgI3, in which
unique features allow binding to CEACAM1. Bioinformatic assess-
ment revealed that this newly identified IgI3 fold is not exclusively
present in GBS but is predicted to be present in adhesins from
other clinically important human pathogens. In agreement with this
prediction, we found that CEACAM1 binds to an IgI3 domain found
in an adhesin from a different streptococcal species. Overall, our
results indicate that the IgI3 fold could provide a broadly applied
mechanism for bacteria to target CEACAMs.
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Introduction
The Gram-positive bacterium Streptococcus agalactiae, also known
as group B Streptococcus (GBS), is a major cause of pneumonia,
septicaemia and meningitis in human neonates (Seale et al, 2017;
Hall et al, 2017). Despite public health interventions, GBS is esti-
mated to cause 410,000 infant infections and 150,000 stillbirths per
year (Seale et al, 2017). From a total of 10 different serotypes, GBS
belonging to serotypes Ia, Ib, II, III and V are most commonly asso-
ciated with disease cases worldwide (Edmond et al, 2012). Cellular
adhesion to epithelial surfaces is the first critical step preceding
infection with GBS and many other pathogens (Patras & Nizet,
2018). Bacterial colonisation is a multifactorial process that requires
expression of adhesins that target extracellular matrix (ECM) consti-
tuents and/or host cell receptors (Pietrocola et al, 2018; Shabayek &
Spellerberg, 2018). Accordingly, GBS express a diverse array of
surface adhesins and the exact repertoire varies from strain to
strain, reflective of high plasticity of the GBS genome (Tettelin et al,
2005; Chen, 2019; Gori et al, 2020). Consequently, individual GBS
strains differ in the host receptors that can be targeted during coloni-
sation. The adhesins likely function cooperatively to facilitate persis-
tent contact between the bacterial cell and the host, promoting
cellular adhesion and invasion.
GBS interacts with several ECM constituents and the molecular
mechanisms underpinning these interactions are well defined. The
adhesins currently known to interact with ECM components are the
fibrinogen-binding adhesins Srr1, FsbA, FsbB and FsbC (Schubert
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et al, 2002; Gutekunst et al, 2004; Seo et al, 2012; Buscetta et al,
2014), the keratin 4-binding adhesin Srr1 (Samen et al, 2007), the
fibronectin-binding adhesins BsaB and SfbA (Jiang & Wessels, 2014;
Mu et al, 2014), and the collagen-binding adhesin PilA (Banerjee
et al, 2011). These interactions promote epithelial colonisation (Schu-
bert et al, 2004; Samen et al, 2007; Sheen et al, 2011; Wang et al,
2014) as well as cellular invasion and/or invasive disease (Tenen-
baum et al, 2005; van Sorge et al, 2009; Banerjee et al, 2011; Seo
et al, 2012; Mu et al, 2014; Deng et al, 2019). Generally, our knowl-
edge of the mechanisms that GBS utilises to directly adhere to host
cells is limited (Bolduc & Madoff, 2007; Patras & Nizet, 2018; Pietro-
cola et al, 2018); a adhesin binds a1b1-integrin to promote epithelial
cell internalisation (Bolduc & Madoff, 2007), BspC adhesin binds
vimentin (Deng et al, 2019), and the BspA adhesin interacts with
gp340, a mucin-like glycoprotein associated with the surface of
mucosal tissues (Rego et al, 2016). However, the host receptor targets
of several putative adhesins remain uncharacterised, including Rib,
Sip, LrrG, HvgA and BibA proteins (Stalhammar-Carlemalm et al,
1993; Brodeur et al, 2000; Santi et al, 2007; Tazi et al, 2010). Conse-
quently, it is expected that several GBS adhesin–host factor interac-
tions remain uncharacterised. Their identification is important for
development of a vaccine or anti-bacterial strategies that interfere
with GBS mucosal colonisation (Michel et al, 1992; Larsson et al,
1996; Heath, 2016; Pietrocola et al, 2018).
We report here that a subset of GBS strains interact with carci-
noembryonic antigen-related cell adhesion molecules (CEACAM)
receptors. Human CEACAMs are a family of 12 cellular receptors
belonging to the immunoglobulin (Ig) superfamily (IgSF) that are
commonly expressed on epithelial cells, endothelial cells and leuco-
cytes (Gray-Owen & Blumberg, 2006). CEACAMs regulate immune
responses through formation of homophilic and heterophilic interac-
tions (Kuespert et al, 2006; Gray-Owen & Blumberg, 2006; Bonsor
et al, 2015b). These properties allow CEACAMs to regulate multiple
physiological and pathophysiological processes including cell-to-cell
communication, epithelial differentiation, apoptosis and regulation
of pro-inflammatory reactions (Gray-Owen & Blumberg, 2006;
Khairnar et al, 2015, 2018; Helfrich & Singer, 2019). Each CEACAM
is composed of an N-terminal domain with V-set (IgV) fold, which
promotes CEACAM-CEACAM interactions, and varying numbers of
C2-set (IgC2) folds (Zhou et al, 1993; Watt et al, 2001; Bonsor et al,
2015a, 2015b). Interestingly, human CEACAMs have been identified
as docking receptors for Gram-negative bacteria (Chen & Gotschlich,
1996; Virji et al, 1996; Hill et al, 2001; Conners et al, 2008; Tchoupa
et al, 2014; Tchoupa et al, 2015; Javaheri et al, 2016; K€oniger et al,
2016; Brewer et al, 2019). The characterised bacterial adhesins
include Opa of Neisseria spp., HopQ of Helicobacter pylori, UspA1 of
Moraxella catarrhalis, P1 of Haemophilus influenzae, Dr adhesins of
Escherichia coli and CbpF of Fusobacterium spp. Interaction of these
adhesins with human CEACAMs promotes cellular adhesion, cellu-
lar invasion, translocation of virulence factors and tissue penetra-
tion (Billker et al, 2002; Korotkova et al, 2008; Tchoupa et al, 2014;
Tchoupa et al, 2015; K€oniger et al, 2016; Javaheri et al, 2016; Islam
et al, 2018). Of note, these CEACAM-binding bacterial adhesins are
structurally distinct, implying that they arose through convergent
evolution. Since CEACAMs have not previously been reported to
interact with Gram-positive bacteria, it was therefore of consider-
able interest to characterise the mechanism by which GBS binds to
CEACAM receptors.
We used biochemical and cellular assays to reveal that the GBS
surface protein b binds specifically to human CEACAM1 and
CEACAM5 and that an IgSF domain in b promotes the binding.
Through structural methods, we demonstrate that the IgSF domain
in b protein contains unique structural features and represents a
previously unrecognised variant of the IgI fold, which we termed
the I3-set fold (IgI3). Homologs of b-IgI3 were identified in adhesins
from several human bacteria including pathogens. We confirmed
that CEACAM1 recognised one of these IgI3 variants and two strep-
tococcal species. Together, these findings suggest that the interac-
tion between bacterial IgI3 domains and CEACAMs may be of
general importance for host barrier colonisation.
Results
The group B Streptococcus surface b protein binds CEACAM1
GBS can successfully adhere to human epithelial cell lines, includ-
ing vaginal, cervical and airway epithelial cell lines (Patras &
Nizet, 2018). Yet, knowledge of the specific host factors that can
be targeted by GBS for adhesion is limited. As CEACAM receptors
are mucosal docking targets for microorganisms (Tchoupa et al,
2014), we hypothesised that GBS interacts with CEACAM recep-
tors. Given that individual GBS strains are likely to vary in their
molecular adhesion mechanisms due to genomic plasticity (Tettelin
et al, 2005; Chen, 2019; Gori et al, 2020), we tested interaction of
rCEACAM1 with a panel of genetically diverse genome-sequenced
GBS strains. We used CEACAM1 in the screen as it binds all
known bacterial ligands of CEACAMs. Using rCEACAM1
(Fig EV1A), we observed binding to GBS strains including refer-
ence strains A909 and H36B (Figs 1A and EV1A). To further test
the specificity of the interaction, we also screened the ability of
rCEACAM1 to interact with a variety of other Gram-positive
species including Streptococcus spp., Enterococcus spp. and Staphy-
lococcus spp. Notably, rCEACAM1 only bound to the indicated
GBS strains (Fig 1A). These data reveal for the first time that GBS
can bind to human CEACAM1 receptor.
Next, we aimed to identify the GBS adhesin responsible for bind-
ing rCEACAM1. We utilised the GBS genome comparison dataset of
Tettelin et al. (2005), which includes rCEACAM1 binding (A909 and
H36B) and non-binding (18RS21 and NCTC10/84) strains, to iden-
tify genes encoding cell wall-anchored proteins that were associated
with rCEACAM1-binding phenotype. We identified that genomic
island of diversity region 3.1 was present in rCEACAM1-binding
strains (A909 and H36B) and absent in non-binding strains (515,
COH1, NEM316 and NCTC10/84). This region encodes a cell wall-
anchored protein known as b protein, or simply b, that is encoded
by bac. To test the hypothesis that b protein was responsible for
CEACAM1 interaction, we screened rCEACAM1 binding to a broader
collection of GBS isolates (Fig 1B) and observed that CEACAM1
binding correlated with carriage of bac (Heden et al, 1991; Lindahl
et al, 2005). The intensity of rCEACAM1 binding differed between
interacting GBS strains, which may reflect differences in b expres-
sion. Indeed, b protein expression levels, detected using anti-b
serum (Fig EV1B), correlated with rCEACAM1-binding capacity
(Fig 1C). Finally, we tested whether CEACAM1 binding was depen-
dent on b protein expression. Deletion of bac in the GBS A909
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Figure 1. Human CEACAM1 binds to group B Streptococcus (GBS) via the surface-expressed b protein.
A, B Binding of recombinant (r)CEACAM1 (CC1)-HIS (10 lg/ml) to (A) a panel of Gram-positive bacteria, namely Enterococcus faecalis, Enterococcus faecium, group A
Streptococcus (GAS), group B Streptococcus (GBS), group C Streptococcus (GCS), group G Streptococcus (GGS), Streptococcus pneumoniae, Staphylococcus aureus, (B) an
expanded collection of GBS isolates, with serotype and carriage of bac gene shown. rCC1 binding to live bacteria was quantified by a secondary anti-His-FITC
monoclonal antibody (mAb). Mean and standard deviation (SD) values are reported for n = 3 independent experiments. In (B), GBS strains from left to right are
A909, BS39, 515, BS22, H36B, BS29, 18RS21, BM110, COH1, SBL3066, NCTC10/84, SB35, SB10, SB20, BS26.
C Correlation between rCC1-binding capacity and b protein expression in GBS strains, respectively. b protein expression was quantified using rabbit anti-b protein
serum and a secondary PE-conjugated goat anti-rabbit-IgG. rCC1 binding to live bacteria was quantified by a secondary anti-His-FITC mAb. Mean binding values
from n = 3 independent experiments.
D Concentration-dependent binding of rCC1-HIS to wild type (WT), Δbac and Δbac + pLZ.bac complemented A909 strains. Mean and SD values are reported for n = 3
independent flow cytometry experiments.
E Pull-down of human rCC1-HIS (30 lg/ml) by GBS strain A909 strain, detected using Western blot analysis.
F Human rCC1-HIS (30 lg/ml) binding to GBS A909 and A909Δbac strains analysed by pull-down experiments followed by Western blot analysis.
G Western blot analysis of rCC1-HIS (30 lg/ml) binding to purified b protein, but not to control GBS surface proteins a and Rib. Panel on the left show staining of
proteins after separation by SDS-PAGE.
H, I Binding of purified b protein to dynabeads (DB) coated with rCC1 (DB.CC1) or control. Binding of b protein was detected using mouse anti-b serum or normal
mouse serum (NMS), and PE-conjugated goat anti-mouse-IgG. (H) shows mean and SD values compiled from n = 3 independent replicates, and (I) shows
representative flow cytometry plots using 10 lg/ml rCC1.
Data information: Fluorescence of bacteria (A, B, C and D) and DB (H and I) was measured by flow cytometry. Western Blot in (E, F and G) employed mouse anti-CC1
mAb (clone C5-1X/8) and HRP-conjugated goat anti-mouse-IgG pAb.
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reference strain abolished rCEACAM1 binding, whilst complementa-
tion with a vector carrying the bac gene re-established rCEACAM1
binding (Figs 1D and EV1C). Mutation of genes encoding other GBS
surface adhesins or capsule did not influence interaction with
rCEACAM1 (Fig EV1C). Additionally, we were able to pull down
rCEACAM1 with GBS A909 (Fig 1E), but not the Δbac strain
(Fig 1F). Direct interaction of rCEACAM1 with purified b protein,
but not with purified GBS surface proteins Rib or a, was demon-
strated by Western blot analysis (Fig 1G). Finally, b protein bound
to CEACAM1-coated dynabeads (DB), but not control beads, in a
concentration-dependent manner (Fig 1H and I). Together, these
data unequivocally show that GBS specifically binds to human
CEACAM1 through expression of b protein.
CEACAM1 binds to an IgSF domain in b protein
b protein is a multifunctional protein and interacts with several
proteins of the human immune system, including factor H, Siglec-
5, Siglec-7, Siglec-14 and IgA, through distinct domains (Fig 2A)
(Lindahl et al, 1990; Heden et al, 1991; Areschoug et al, 2002b;
Carlin et al, 2009; Nordstr€om et al, 2011; Ali et al, 2014; Fong
et al, 2018). To pinpoint the b protein domain interacting with
CEACAM1, we expressed and purified recombinant b protein
domains (B6N, IgABR, B6C, IgSF and b75KN) from E. coli (Fig 2B)
and tested their interaction with rCEACAM1. These domains
include a part of b called IgSF because the domain was predicted
to adopt an immunoglobulin superfamily (IgSF) fold (Bateman
et al, 1996; Lindahl et al, 2005). IgSF folds are composed of
around 100 amino acids comprising two b sheets that pack face-
to-face. rCEACAM1 bound in a concentration-dependent manner
to DB coated with the biotinylated IgSF domain, but not to DB
coated with other b protein domains or biotinylated-HSA (Fig 2C).
As a control, we included rSiglec-5, which interacted only with DB
coated with the B6N domain as described previously (Fig 2C;
Nordstr€om et al, 2011). Furthermore, DB coated with rCEACAM1
interacted with the IgSF domain, but not HSA, coupled to strepta-
vidin (Fig 2D). Thus, the IgSF domain in b specifically binds to
human CEACAM1. We assessed whether the IgSF domain shared
structural homology with other resolved IgSF structures. Structural
predictions of the b-IgSF domain suggested resemblance to a V-set
Ig (IgV) domain identified in SrpA, a cell surface-anchored protein
in Streptococcus sanguinis (Fig 2E; Bensing et al, 2016). However,
rCEACAM1 did not bind to the surface of a SrpA-expressing
S. sanguinis strain (Appendix Fig S1). We denoted the IgSF fold in
b as b-IgSF.
The CEACAM1-4L isoform possesses four Ig-like domains
(Appendix Fig S2A; Gray-Owen & Blumberg, 2006), including the N-
terminal IgV-like domain that forms the homo- and heterophilic inter-
actions implicated in the CEACAM-mediated functions (Bonsor et al,
2015b). All bacterial ligands characterised to date for CEACAM1 target
the N-terminal IgV-like domain. To identify the CEACAM1 domain
targeted by b-IgSF, we tested whether domain-specific CEACAM1
monoclonal antibodies (mAb) could inhibit the interaction of b-IgSF
with CEACAM1-coated DB. Only a mAb that blocks the N-terminal
domain of CEACAM1 abolished the interaction with b-IgSF (Fig 2F;
Appendix Fig S2B). Similarly, the H. pylori protein HopQ, which binds
to the N-terminal domain (Bonsor et al, 2018), blocked the b-IgSF-
CEACAM1 interaction (Appendix Fig S2C). To test for direct interac-
tion with the N-terminal domain, we coated DB with rCEACAM1-N or
rCEACAM1-A1B1A2 (Appendix Fig S2D) and observed concentration-
dependent binding of b-IgSF only to DB coated with rCEACAM1-N
(Fig 2G). In the reciprocal experiment, rCEACAM1-N, but not
rCEACAM1-A1B1A2, bound to DB coated with b-IgSF (Appendix Fig
S2E).
The b-IgSF domain binds with high affinity to human CEACAM1
and CEACAM5
Bacterial adhesins of CEACAM1 often also bind to the N-terminal
domain of CEACAM3, CEACAM5 and CEACAM6, reflecting the
high sequence (~90% identity) and structural homology between
CEACAM family members (Popp et al, 1999; Gray-Owen & Blum-
berg, 2006). However, no bacterial adhesins to date bind
CEACAM8. To ascertain the CEACAM-binding profile for b-IgSF, we
measured the affinity of b-IgSF for unglycosylated N-terminal
domains of these five CEACAMs, purified from E. coli, by isother-
mal calorimetry (ITC) (Fig 3A; Appendix Table S3). b-IgSF
bound with high affinity to rCEACAM1-N (KD = 96  2 nM) and
rCEACAM5-N (KD = 152  27 nM), but did not bind to rCEACAM3-
N, rCEACAM6-N or rCEACAM8-N. The affinities of the (b-IgSF)-
(CEACAM1-N) and (b-IgSF)-(CEACAM5-N) interactions were
comparable to those reported for other bacterial ligands (Korotkova
▸Figure 2. The IgSF domain in the b protein of GBS binds to the N-terminal domain of CEACAM1.A Schematic representation of the b protein (Heden et al, 1991). The first residue of each domain is indicated. XPZ is a proline-rich repeat region (Areschoug et al,
2002a). Known human ligand binding partners are indicated above each respective domain. IgA binds to a region denoted IgABR. Factor H binds the b75K region, but
does not bind via XPZ.
B Staining of recombinant b protein domains (B6N, IgABR, B6C, b-IgSF and b75KN) after separation by SDS-PAGE. Recombinant proteins were expressed in E. coli. b
protein purified from GBS is used as a control. Dotted boxes signal proteins of expected size.
C Binding of rCC1-His or rSiglec5-Fc to dynabeads (DB) coated with b protein domains. Mean and SD values are reported for n = 2 replicates.
D Binding of varying concentrations of b-IgSF or human serum albumin (HSA) coupled to streptavidin-PE (SPE), to DB coated with CC1 (DB.CC1) or control protein (DB).
Mean and SD values are reported for n = 6 replicates.
E Structure of the relevant (Siglec-like sialic acid-binding) domain of the highest-scoring template 5KIQ (SrpA binding region), and predicted three-dimensional model
of the IgSF domain from the b protein, constructed from the Hhpred alignment using MODELLER (Webb & Sali, 2016).
F Inhibition of b-IgSF binding to DB.CC1 by anti-CC1-N mAb (clone CC1/3/5-Sab), but not by anti-CC1-A1B1 mAb (clone B3-17). b-IgSF-biotin was coupled to SPE. Mean
and SD values are reported for n = 6 replicates.
G Concentration-dependent binding of b-IgSF to DB coated with 100 lg/ml CC1 (DB.CC1), CC1-N (DB.CC1-N) or CC1-A1B1A2 (DB.CC1-A1B1A2). Assays utilised proteins
coupled to SPE. Mean and SD values are reported for n = 6 replicates.
Data information: Fluorescence of DB in (C, D and F) was measured by flow cytometry.
4 of 20 The EMBO Journal 40: e106103 | 2021 ª 2021 The Authors
The EMBO Journal Nina M van Sorge et al.
et al, 2008; Bonsor et al, 2018). As the binding of b-IgSF is weaker
to the isolated N-terminal domain compared to glycosylated
CEACAM1 (Fig 2G), other CEACAM1 domains may stabilise the
interaction, as reported for the HopQ-CEACAM1 interaction (Bonsor
et al, 2018). To confirm that the CEACAM-binding profile of the
protein is valid when expressed on the surface of GBS bacteria, we
tested binding of the full-length glycosylated rCEACAMs to GBS by
flow cytometry. The b-expressing GBS A909 strain only recognised
CEACAM1 and CEACAM5 (Fig 3B). Specificity for this subset was
generally confirmed in a wider panel of b-expressing GBS strains
(Appendix Fig S3), though variation existed in CEACAM5 binding.
Although several b-expressing GBS strains did not bind CEACAM5,
the b-IgSF domain displayed 100% sequence conservation amongst
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S4), indicating that intrastrain variation in CEACAM5 binding is
most likely due to differential b expression.
Expression of human CEACAMs on epithelial cells enhances
GBS adhesion
As CEACAM engagement leads to enhanced cellular adhesion of
Gram-negative microorganisms, we hypothesised that CEACAMs
could represent a novel cellular adhesion mechanism for GBS.
Therefore, we tested the binding of strain A909 to well-
characterised CEACAM-expressing HeLa cells (Fig 4A; Bos et al,
1998). Consistent with rCEACAM binding, a higher percentage of
the A909 inoculum was recovered from the CEACAM1- and
CEACAM5-expressing HeLa cells in comparison to all other HeLa
cell lines (Fig 4A). Increased binding of GBS to human CEACAM1-
expressing HeLa cells was confirmed by confocal microscopy
(Fig 4B). To ensure that the CEACAM-observed binding was not
influenced by the background of the cell line, we assessed GBS
adhesion to CEACAM-expressing CHO cells (Hollandsworth et al,
2020). Also, a higher percentage of the GBS inoculum was
A
B
Figure 3. b-IgSF binds with high affinity to human CEACAM1 and CEACAM5.
A Representative isothermal titration calorimetry (ITC) binding curves of CEACAM-N domains and b-IgSF duplicates. Experiments were performed using b-IgSF and N
domains of (r)CEACAM1 (CC1), CEACAM3 (CC3), CEACAM5 (CC5), CEACAM6 (CC6) and CEACAM8 (CC8).
B Representative flow cytometry plots analysing the interaction of rCC1, CC3, CC5, CC6 or CC8 (10 lg/ml) with GBS A909. Fluorescence of bacteria was measured by
flow cytometry. Representative data from n = 3 independent experiments.
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recovered from the CEACAM1- and CEACAM5-expressing CHO
cells in comparison to all other CHO cell lines (Fig 4C). For
unknown reasons, there was considerable variation in GBS adhe-
sion to the CEACAM1- and CEACAM5-expressing CHO cells. This
variation could not be attributed to unstable CEACAM expression,
as our cell lines expressed CEACAM at consistent levels (Fig EV2A
and B). It is possible that the variation in GBS adhesion could be
due to differences in CEACAM-expression density by CHO cells or
due to differences in b expression by GBS strains in replicated
experiments.
To confirm that adhesion of the GBS strain A909 to the
CEACAM1-expressing CHO cell line was dependent on b protein, we
also assessed binding of the bac deletion mutant and the comple-
mented strain in this same system. GBS adherence was abolished by
mutation of the bac gene, and the phenotype could be recapitulated
by the complemented mutant (Fig 4D). This result was confirmed
by confocal microscopy (Fig EV2C). In agreement with the results
obtained with purified proteins (Fig 2F), the binding of b-expressing
GBS to CEACAM1-expressing CHO cells was inhibited by blocking


























































































































































Figure 4. GBS exploit human CEACAM for enhanced adhesion to epithelial cells.
A Adherence of GBS A909 to human CEACAM1 (CC1)-, CEACAM3 (CC3)-, CEACAM5 (CC5)-, CEACAM6 (CC6)- or CEACAM8 (CC8)-expressing, or an empty vector control,
HeLa transfectants at MOI of 10 for 30 min. Mean and SD for n = 4 independent replicates are shown.
B Confocal imaging of FITC-labelled GBS A909 strain adhesion to human CC1-expressing or empty vector control HeLa transfectants. Cell membranes were stained
with AF-647-conjugated wheat germ agglutinin (WGA) (red) and nuclei with DAPI (blue). Scale bar: 26 lm.
C Adherence of A909 to human CC1-, CC3-, CC5-, CC6- or CC8-expressing, or an empty vector control, CHO transfectants at MOI of 10 for 30 min. Mean and SD from
n = 5 independent replicates is displayed.
D Adhesion of WT, Δbac and Δbac + pLZ.bac complemented A909 strains to human CC1- or CC5-expressing CHO transfectants, or empty vector control cells. Mean
and SD from n = 5 independent replicates is displayed.
E, F Adhesion of FITC-labelled A909 to human CC1-expressing, or control, CHO transfectants at an MOI of 10. Cell lines were detached and then incubated with FITC-
labelled A909 for 30 min at 4°C. The percentage of fluorescent cells was calculated for each population. Representative flow cytometry plots are shown (E), and the
integrated results displaying the mean and SD from 3 independent replicates are reported in (F).
G Adhesion of FITC-labelled A909 strains to human CC1-expressing or control CHO transfectants at MOI of 10. Cell lines were detached and then incubated with
FITC-labelled A909 strains for 30 min at 4°C. Mean and SD for each population for n = 6 independent replicates is displayed.
Data information: Fluorescence of cells in (E, F and G) was measured by flow cytometry analysis, where the percentage of fluorescent cells was calculated. The number
of bacteria adhered to cell monolayers in (A, C and D) were quantified by growth on Todd-Hewitt agar and enumeration of colony forming units (CFU). Data in (A, C, D, F
and G) were analysed by repeated one-way ANOVA with Sidak’s multiple comparisons. *P < 0.05 and **P < 0.01.
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Moreover, pre-incubation of A909 with rCEACAM1-N, but not
rCEACAM8-N, impaired adhesion to CEACAM1-expressing CHO
transfectants (Fig EV2E). This indicates that the CEACAM1-N and
b-IgSF domains were both responsible for the cellular adhesion
phenotype.
To rule out the possibility that differences in adhesion of A909
wild-type and Δbac strains to CHO cells reflected interstrain varia-
tion in growth rates during adhesion at 37°C, we developed an alter-
native assay in which we assessed adhesion of FITC-labelled GBS
strains to detached cell lines during incubation at 4°C. A higher
percentage of CEACAM1-expressing CHO cells were FITC-positive
upon incubation with A909 in comparison to control cells (Fig 4E
and F). As expected, adhesion of FITC-labelled A909 to the
CEACAM1-expressing CHO cell was abolished by mutation of bac
(Figs 4G and Fig EV2F). Collectively, the data therefore indicate that
binding to human CEACAM receptors, via b, is a novel cellular
adhesion mechanism for GBS.
Crystallography reveals that the IgSF domain in b adopts a novel
Ig fold, the IgI3 fold
To gain insights into b-IgSF binding mechanisms, we aimed to solve
its structure. We solved the structure in complex with CEACAM1-N
at a resolution of 3.25 A (Fig 5A). The asymmetric unit contains
two molecules of the (b-IgSF)-(CEACAM1-N) complex, which are
similar to each other when superimposed (r.m.s.d 0.20 A). All anal-
ysis of the (b-IgSF)-(CEACAM1-N) complex has been performed
with chains B and C of the co-crystal complex. The b-IgSF domain
has the characteristic features of an Ig fold, principally a pair of b
sheets built of anti-parallel b strands that surround a hydrophobic
core (Fig 5B). IgSF domains can be classified into (variable) V-set,
(constant) C-set or (intermediate) I-set, with differentiation based
on the number and placement of b-strands between the conserved
cysteine residue disulphide bridge (Fig 5C; Wang & Springer, 1998;
Wang, 2013). The V-set Ig (IgV) domains contain ten b strands with
four strands found on one sheet (ABED) and six strands on the
other (A0GFCC0C0 0). C-set Ig (IgC) domains lack the A0 and C0 0
strands and are further grouped into C1 or C2 based on presence or
absence of the D strand, respectively. I-set Ig (IgI) domains lack the
C0 0 strand and are classified into I1 or I2 based on presence or
absence of a D strand, respectively. The b-IgSF domain has two b-
sheets labelled ABED and A0GFC, with sheets connected by the BC,
EF, CD and AA0 loops (Fig 5B). Therefore, b-IgSF has an I-set fold
topology that most closely resembles an I1-set domain (Fig 5C).
However, b-IgSF lacks cysteines and disulphide bridges that are
characteristic for I-set folds. Furthermore, the b-IgSF domain
possesses a truncated C strand that is directly followed by 1.5-turn
a-helix (Fig 5C). These features were not observed in the struc-
turally characterised IgI1 domains in the DALI or PDBeFOLD data-
bases that b-IgSF most closely resembled, including macrophage
colony stimulating factor 1 (MCS-F) and intracellular adhesion
molecules 3 (ICAM-3) (Figs 5D and Fig EV3A and B). Therefore,
the topology of b-IgSF domain represents a previously unrecognised
IgI fold subtype, denoted here as I3-set Ig (IgI3) domain. Accord-
ingly, the domain in b will now be referred to as b-IgI3. The unique
features of this domain are (a) the absence of cysteine residues, (b)
absence of C0 and C0 0 strands and (c) a truncated C strand that is
directly followed by a 1.5-turn a-helix. Of note, the unique b-IgI3
region stretching from the C to the D strand possesses protruding
hydrophobic residues, such as F42, located between the C strand
and the a-helix, L46 located in the a-helix, and V53 located in the
CD loop (Fig 5E).
Identification of interacting residues in the
(b-IgI3)-(CEACAM1-N) complex
CEACAMs form their homophilic and heterophilic interactions
through the A0GFCC0C0 0 face of the V-set domain (Figs 5A and 6A).
Bacterial ligands also bind to the A0GFCC0C0 0 face (Virji et al, 1999;
Villullas et al, 2007; Conners et al, 2008; Korotkova et al, 2008;
Bonsor et al, 2018; Moonens et al, 2018; Brewer et al, 2019). The
H. pylori ligand HopQ uses a coupled folding and binding mecha-
nism (Bonsor et al, 2018), and simulated docking indicated that the
E. coli ligand AfaE binds to the CEACAM dimerisation interface
through the BE strands and DE loop of an incomplete Ig fold (Ander-
son et al, 2004; Korotkova et al, 2008).
The structure determination by X-ray crystallography (Fig 6B;
Appendix Table S4) of the complex of b-IgI3 and CEACAM1-N at
3.25 A resolution showed that b-IgI3 also binds to the A0GFCC0C0 0
face of CEACAM1 through residues located in the C to D strand
region including the a-helix (Figs 6C and EV3C). To identify the
residues forming contact sites between b-IgI3 and CEACAM1-N
within the co-crystal, we used the NCONT sub-program of CCP4
(Appendix Table S5). Figure 6B shows the interacting residues on
the surfaces of the two molecules. Specifically, L46 in the a-helix of
b-IgI3 interacts by van der Waals forces with F29 and L95 (dis-
tances 3.34 A and 3.59 A) located in the C and G strands of
CEACAM1, respectively (Fig EV3D; Appendix Table S5). In addi-
tion, the protruding b-IgI3 residue V53 is within close contact of I91
(distance 3.36 A, F strand), Q44 (distance 2.50 A, C to C’ loop) and
S32 (distance 3.41 A, C strand) of CEACAM1, D55 is within close
contact of Y34 (distance 3.50 A, C strand) and G41 (distance
▸Figure 5. The Ig-like domain of b protein represents a new IgI fold subtype.A Dimer co-crystal structure of b-IgSF (blue) and CEACAM1-N (CC1-N; red).
B Molecular structure of b-IgSF, in which each b-strand is coloured differently. The 1.5-turn a-helix shown in grey is located between the C strand and the D strand.
C Illustration of the secondary structure organisation of the V-set, C1-set, C2-set, I1-set, I2-set and I3-set domains. Each secondary structure is composed of varying
combinations of the b-strands A, A0 , B, C, C0 , C0 0 , D, E, F, G. Disulphide bridges between the B strand and F strand are represented as a black dashed lines. The C-set
domains lack the A0 and C0 0 strands and are subtyped into C1-set and C2-set based on presence and absence of the D strand, respectively. The I-set domains lack C0 0
strand and are subtyped into C1-set and C2-set based on presence and absence of the D strand, respectively. The IgSF fold from b protein has the I3-set domain,
characterised by absence of disulphide bridge, presence of the D strand, and presence of a truncated C strand followed by a 1.5-turn a-helix.
D Comparison of b-IgI3 (blue) with the most similar folds; the IgI1 domain of MCS-F (turquoise) and the IgI1 domain of ICAM-3 (magenta).
E The molecular surface mesh of b-IgI3 residues showing protruding residues located between the C and D strands in blue.
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2.90 A, C to C’ loop) of CEACAM1, and F42 is in close contact of
L95 (distance 2.87 A, G strand) of CEACAM1 (Appendix Table S5).
Further contacts are made by b-IgI3 through residues L40, D41,
S43, T47, N50, P51, S52, S54, I57, T59 and Y61 and CEACAM1 resi-
dues G30, Y31, Y34, D40, A49, T56, I91, S93, D94 and V96 of
CEACAM1, respectively (Appendix Table S5). No conformational
changes were observed in CEACAM1 upon binding of b-IgI3
(Fig EV3E).
Based on the co-crystal data, we hypothesised that b-IgI3 residue
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(Figs 6C and EV4B). Additionally, b-IgI3 residue V53 appeared criti-
cal for contacting CEACAM1-N residue I91, and b-IgI3 residue F42
was critical for contacting CEACAM1-N residue L95. We generated
alanine mutations in b-IgI3 at these positions, and others, based on
their contact with CEACAM1. ITC binding studies of these b-IgI3
mutants to “wild-type” unglycosylated CEACAM1-N revealed that
the mutant b-IgI3L46A failed to bind to rCEACAM1-N. Two additional
mutants, b-IgI3V53A and b-IgI3D55A, had reduced affinity to bind
rCEACAM1-N (KD = 562  44, 690  52 nM, respectively; Fig EV4A;
Appendix Table S6). In contrast, b-IgI3F42A bound with higher
affinity (KD = 1615 nM). We also tested the ability of unglycosy-
lated rCEACAM1-N to bind DB coated with the b-IgI3 variants
(Fig 6D). In this analysis, rCEACAM1-N displayed significantly




Figure 6. The IgI3 domain of b protein binds CEACAM1 through the unique a-helix and CD loop.
A Molecular structure of CEACAM1 (CC1)-N, in which each strand of the IgV structure is coloured differently.
B Molecular structure of the b-IgI3 and CC1 N-terminal domain co-complex. Residues that form the b-IgI3-CC1 interface are highlighted.
C Close-up of the b-IgI3 (light blue) interface with CC1-N (pink), including highlighting of residues important for forming b-IgI3 (blue) and CC1-N (red) interactions. The
GFCC0C0 0 strands of CC1-N are shown and labelled, whilst the C to D strands of b-IgI3 are shown and labelled.
D Binding of rCC1-N to dynabeads (DB) coated with b-IgI3 wild type (WT) or mutants. Mutation of b-IgI3 residues 42, 46 and 53 lead to significant changes in CC1-N
binding capacity.
E Binding of b-IgI3 coupled to Streptavidin-PE to DB coated with rCC1-N wild type or variants. Mutation of CC1-N residues 29, 44, 89, 91 and 95 lead to significant
changes in b-IgI3 binding capacity.
Data information: Fluorescence of DB in (D and E) was measured by flow cytometry. Mean and SD values in (D and E) are displayed for n = 3 independent replicates.
Statistical significance was calculated using t test for (D and E), where *P < 0.05; **P < 0.01.
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significantly enhanced binding to DB coated with b-IgI3F42A.
Together, these data indicate that the L46, V53 and D55
residues of b-IgI3 are critical for the binding to CEACAM1. These
residues were observed to be conserved in 57 b protein
sequences (Appendix Fig S4).
For CEACAM1-N, the crystal structure of the complex indicated
that b-IgI3 interacts with the dimer interface, contacting several
residues which are important for CEACAM1 homodimerisation and
for binding to other bacterial adhesins. We hypothesised that resi-
dues F29, I91 and L95 of CEACAM1 are critical for contacting b-
IgI3 (Figs 6C and EV3C and D) and generated alanine mutants at
these and several other positions in the homodimerisation inter-
face. In ITC analysis with unglycosylated CEACAM1-N proteins,
both CEACAM1-NF29A and CEACAM1-NI91A failed to bind b-IgI3
(Fig EV4B; Appendix Table S6). Additionally, CEACAM1-NQ89A
also lacked ability to bind b-IgI3. Two mutants, CEACAM1-NQ44A
and CEACAM1-NL95A, resulted in a 10-fold decrease in binding affi-
nities (KD = 996  116 and 1350  460 nM, respectively) whilst
two further mutants, CEACAM1-NV96A and CEACAM1-NN97A,
displayed only a modest decrease (4-fold) in binding affinities
(KD = 370  4 and 490  120 nM, respectively). In addition, we
tested the ability of b-IgI3 coupled to streptavidin to interact with
DB coated with the unglycosylated wild-type or mutant
rCEACAM1-N (Fig 6E). Binding was significantly reduced for
CEACAM1-NF29A, CEACAM1-NQ89A and CEACAM1-NI91A, as well
as for CEACAM1-NQ44A and CEACAM1-NL95A, confirming that resi-
dues F29, Q89 and I91 are major targets of b-IgI3 binding. I91 has
also been identified as a critical CEACAM1 residue for interaction
with M. catarrhalis (Conners et al, 2008), Neisseria spp. (Virji
et al, 1999; Villullas et al, 2007), H. influenzae (Hill et al, 2001)
and Fusobacterium spp (Wang, 2013). Though Q89 in CEACAM1
is critical for interaction with b-IgI3 and other bacterial ligands,
Q89 was not in close contact with any b-IgI3 residues. It is possi-
ble that mutation of the CEACAM1 residue Q89 to an alanine
forms a cavity on the surface that I91 and surrounding residues of
CEACAM1 attempt to fill though alternative rotomer conformations
that subsequently prevents interaction with b-IgI3. In summary,
contact of residue L46 in b-IgI3 with CEACAM1 residue F29, and
residue V53 in b-IgI3 with CEACAM1 residue I91, provide the criti-
cal interactions. Additional stability is gained through b-IgI3 resi-
dues F42 and D55.
Comparison of b-IgI3- and HopQ-bound CEACAM1 structures
Comparison of the (b-IgI3)-(CEACAM1-N) complex and the (HopQ)-
(CEACAM1-N) complex, revealed that the same set of CEACAM1
residues are contacted by both b-IgI3 and HopQ (Fig EV3F).
However, HopQ is structurally completely unrelated to b-IgI3 (Bon-
sor et al, 2018). HopQ uses an intrinsically disordered loop, that
folds into a b hairpin and a small helix upon binding to CEACAM1.
The b hairpin extends the CEACAM1 A0GFCC0C0 0 face whilst the
small helix straddles the face (Fig EV3F). In contrast, b-IgI3 inter-
acts through the small a helix and loop, with a single residue, L46,
critical for b-IgI3 to fit into a pocket on CEACAM1-N formed by F29
and I91 (Fig 6C). Mutation of any of these residues in b-IgI3 or
CEACAM1-N causes a hole in the protein–protein interface or
collapse of the pocket, respectively, abolishing binding as observed
with our ITC experiments.
b-IgI3 homologs are broadly distributed in human
Gram-positive bacteria
To gain a broader perspective on the possible role of the unique b-
IgI3 structure in bacteria–host interactions, we investigated the
distribution of this domain in the bacterial kingdom through BLAST
analysis. A sequence similar or related to b-IgI3 was identified in
296 proteins predicted to be expressed by human Gram-positive
bacteria, including several human pathogens, such as S. pyogenes,
S. dysgalactiae and S. pneumoniae. These sequences formed several
different clades upon maximum likelihood analysis (Fig 7A). The b-
IgI3 domain was present in a large clade, clade I, which also
included sequences from S. oralis. A second major clade, clade II,
contained sequences from GBS and from other human streptococcal
pathogens including S. pyogenes (also known as group A Streptococ-
cus), S. dysgalactiae and S. mitis. Additionally, sequences closely
related to clade II were detected in S. mitis, S. milleri and S. inter-
medius, forming clade III. Finally, many homologs of b-IgI3 were
present in proteins from a diverse panel of Gram-positive human
pathogens including S. pneumoniae, S. pseudopneumoniae and
Gemella haemolysans. An additional homolog was identified in
Gardnerella vaginalis, a Gram-variable bacterium. The sequences of
b-IgI3 homologs were all located in proteins predicted to be surface-
localised and anchored to the bacterial cell wall.
We predicted the tertiary structure of 11 representative homolog
sequences based on the b-IgI3 crystal structure. These structures
maintained the overall IgI3 fold, including an a-helix and loop
located between the truncated C strand and the D strand
(Appendix Fig S5), except clade XV sequence from G. vaginalis
that lacked the C strand. These data suggest that the IgI3 structure
is broadly distributed in bacterial cell wall-anchored adhesins. We
focused further analysis on clade II that maintains key IgI3 struc-
tures whilst sharing 40% amino acid identity with b-IgI3 (Fig 7B;
Appendix Fig S6A–C). This clade includes the R28 protein, which
is found in S. pyogenes and in GBS (where the same protein is also
called Alp3). R28 is a cell wall-anchored adhesin that is unrelated
to b protein except for the IgI3 domain (Stalhammar-Carlemalm
et al, 1999; Lindahl et al, 2005). To understand the CEACAM1
binding capacity of the putative IgI3 domain in R28, we inspected
whether the critical protruding residues located between C and D
strands in b-IgI3 (Fig 7C) were conserved in the IgI3 domain of
R28. Though the CEACAM1-binding residues of b-IgI3 (F42, L46,
V53 and D55) are not conserved in R28-IgI3 (Fig 7C), two of the
R28-IgI3 residues found at corresponding positions were of
hydrophobic nature as in b-IgI3. Interestingly, additional residue
variation was evident amongst other IgI3 domains (Fig EV5). Since
this result suggested that IgI3 homologs are likely to differ in their
properties, it became critical to analyse whether the R28-IgI3
homolog binds CEACAM1.
Human CEACAMs bind Gram-positive bacteria
expressingb-IgI3 homologs
To determine whether the IgI3 domain in R28 interacts with
CEACAM1, we purified rR28-IgI3 protein domain, that was
expressed in E. coli, and tested interaction with rCEACAM1. DB
coated with biotinylated R28-IgI3 and b-IgI3, but not HSA, interacted
with rCEACAM1 (Fig 7D). In the reverse assay, DB coated with
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rCEACAM1 interacted with R28-IgI3 and b-IgI3, but not HSA,
coupled to streptavidin (Fig 7E). We also confirmed that rCEACAM1
bound to an R28-expressing S. pyogenes strain (Fig 7F). In addition,
rCEACAM1 bound to an Alp3-expressing strain of GBS, which was
expected given that R28 and Alp3 proteins are identical in sequence.
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mediated through the N-terminal domain of CEACAM1, we used
ITC to measure the affinity of R28-IgI3 for unglycosylated N-termi-
nal domains of CEACAM1 (Appendix Fig S7). In this analysis, R28-
IgI3 bound with intermediate affinity (KD = 1050  18 nM,
DH = 4.8  0.3 kcal/mol) to CEACAM1-N. Taken together with
the structural predictions described above, these data indicate that
IgI3 folds present in adhesins from a wider range of Gram-positive
bacterial pathogens can interact with the N-terminal domain of
human CEACAM1, but that individual IgI3 domains may interact
with human CEACAM1 differently.
To dissect whether b-IgI3 and R28-IgI3 interact differently with
CEACAM1, we simulated the docking of IgI3 domains onto human
CEACAM1 and examined the free energy calculations to ascertain
the key IgI3 residues in the complex formation (Appendix Fig S6C).
Residues with binding free energy contributions lower than
2.0 kcal/mol and greater than 2 kcal/mol are identified as key
residues and unfavourable residues, respectively. Simulation of b-
IgI3 and CEACAM1 docking correctly predicted that residues F42,
L46 and V53 were key determinants of CEACAM1 binding, whilst
D55 was an unfavourable determinant (Fig 7G; Appendix Fig S6D).
The binding free energy of the (R28-IgI3)-(CEACAM1-N) complexes
was strong (31.02  6.70 kcal/mol, n = 50 simulations). In
contrast to b-IgI3, residues located in the a-helix of R28-IgI3 were
not identified as key determinants of CEACAM1 binding (Fig 7G;
Appendix Fig S6E). Instead, critical R28-IgI3 residues (K48, I54, I56
and K59) were located in the CD loop and the D strand only.
Mapping of key residues on the surface structure therefore
suggested that b-IgI3 and R28-IgI3 target CEACAM1 through dif-
ferent faces on the IgI3 fold (Appendix Fig S6D and E). Thus, IgI3
domains in different bacterial proteins probably interact with
human CEACAM1 through mechanisms that are not identical but
use the same structural fold.
Discussion
We show here that a novel Ig-like fold in different streptococcal
adhesins promotes binding to human CEACAM receptors. Molecular
analysis of this domain in the b protein from GBS demonstrated that
the Ig-like domain binds to the N-terminal domain of human
CEACAM1 and CEACAM5. We solved the crystal structure of the Ig-
like domain in b and revealed that it represents a novel Ig-fold
structure related to the I-set that is characterised by an absence of
cysteine residues and the presence of a truncated C strand that is
directly followed by a unique 1.5-turn a-helix. As this Ig-like fold of
the I-set has unique features, it was designated IgI3. Whilst cysteine
residues and disulphide bridges are found in Ig folds of prokaryotic
and eukaryotic proteins (Halaby & Mornon, 1998; Bodelon et al,
2013), the absence of cysteine residues has not been documented in
IgI folds to date. In addition, the partial replacement of the C strand
with a 1.5-turn a-helix was not identified in any other Ig fold in a
search of PDB using HHpred (Zimmermann et al, 2018). I-set folds
are rarely found within bacterial proteins as observed through a
search of the SMART database (Letunic & Bork, 2018). This work
therefore presents the first representative structure of a novel Ig-fold
subtype, IgI3, and highlights that unique subtypes of Ig folds remain
to be discovered in biology.
The co-crystal structure of the complex demonstrated that b-IgI3
targets the dimerisation interface of CEACAM1 through a unique
mechanism involving residues in the C strand to D strand loop of b-
IgI3 including the a-helix. In contrast, Opa proteins of Neisseria spp.
are membrane proteins that bind to the CEACAM dimerisation inter-
face through two hypervariable loops (Billker et al, 2000), UspA1 of
M. catarrhalis forms a trimeric coiled-coil that binds to CEACAM
dimerisation interface through a small bend (Conners et al, 2008),
HopQ of H. pylori uses a disordered loop to bind the CEACAM
dimerisation interface (Bonsor et al, 2018), and AfaE of E. coli uses
an incomplete Ig-like domain to target the CEACAM dimerisation
interface (Anderson et al, 2004; Korotkova et al, 2008).
The finding that b-IgI3 homologs are broadly distributed in
Gram-positive bacteria raises many fascinating questions about the
evolutionary history of IgI3-folds and their role in bacterial patho-
genesis. What is the origin of the IgI3-fold? How conserved is the
IgI3-fold structure? How did the IgI3-fold become so widely distrib-
uted? Do all bacterial adhesins containing IgI3 homologs bind
CEACAMs and how is binding conferred? Whilst IgI3 homologs
were found in putative adhesins from several Gram-positive bacte-
ria, there was low conservation of the critical b-IgI3 residues in the
predicted structures of homologs, suggesting that each sequence
may possess different properties. Our study demonstrated that R28-
IgI3 and b-IgI3 both bind the N-terminal domain of CEACAM1,
though stimulated docking suggests that these IgI3 domains bind
through alternative mechanisms. As R28-IgI3-like sequences were
found in proteins from multiple human pathogens, CEACAM-
◀ Figure 7. The unique IgI3 structure is present in Gram-positive bacterial species and evidence for binding CEACAM1.
A Amino acid based maximum likelihood tree of b-IgI3 homologs. Clades of related IgI3 domains are shown, with clade I representative of b-IgI3 domain sequences.
Branches are coloured by bacterial species from which the sequence originates, except those with no species designated that are shown in black. Maximum
likelihood bootstrap values > 60 are shown as a circle, where larger circles indicate a higher bootstrap support value.
B Superposition of the IgI3 domain from b protein (blue) onto predicted IgI3 domain structure of clade II sequence of S. pyogenes R28 protein (red).
C Close-up of the truncated C strand, a-helix and D strand of b-IgI3 (blue) and R28-IgI3 (red), indicating the corresponding R28-IgI3 residues present at sites in b-IgI3
that bind CEACAM1 (CC1).
D Binding of recombinant (r)CC1-HIS to dynabeads (DB) coated with b-IgI3, R28-IgI3 or control. Mean and SD is shown for n = 6 independent replicates.
E Binding of b-IgI3, R28-IgI3 or human serum albumin (HSA) coupled to PE-conjugated streptavidin (SPE), to DB coated with CC1 (DB.CC1). Mean and SD is shown for
n = 6 independent replicates.
F Binding of recombinant rCC1-HIS (10 lg/ml) to R28-expressing GBS strain H1147 and R28-expressing S. pyogenes strain AL368. Data representative of n = 3 replicates.
G The per residue free energy contribution spectrums of b-IgI3/CC1-N interface and R28-IgI3/CC1-N interface. The residues with binding free energy contributions lower
than 2.0 kcal/mol are identified as key (favourable) residues and coloured blue (for b-IgI3) or red (for R28-IgI3). Free energy contributions at 2.0 kcal/mol and
2.0 kcal/mol are indicated by dashed lines. The position of the truncated C strand, a-helix and D strand is shaded for each protein. The mean and standard deviation
is representative of estimates from 50 docked models.
Data information: Statistical significance was calculated using a one-way ANOVA with Sidak’s multiple comparisons for (D and E), where **, P < 0.01. Fluorescence of DB
(D and E) and bacteria (F) was measured by flow cytometry.
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binding may represent an unrecognised adhesion strategy for a
range of Gram-positive bacteria. Of note, the gene encoding b is
encoded on mobile genetic elements that can move between bacte-
ria by horizontal gene transfer (Tettelin et al, 2005). This could
provide opportunities for rapid acquisition of CEACAM binding in
other bacterial species leading to the emergence of strains with
enhanced colonisation properties or virulence. Thus, the exploration
of IgI3-fold and CEACAM receptor interactions is further warranted.
Adhesion to epithelial cells at mucosal surfaces is a prerequisite
for streptococcal colonisation and disease development. For GBS
bacteria, the data presented here show that the IgI3 domain in the b
protein promotes binding to CEACAM1 and CEACAM5 present on
epithelial cell surfaces. This finding is consistent with reports of
CEACAM-interacting Gram-negative bacteria (Virji et al, 1996; Bos
et al, 1998; Tchoupa et al, 2014, 2015; Gutbier et al, 2015; K€oniger
et al, 2016; Javaheri et al, 2016). This is of general importance as it
expands the spectrum of cellular adhesion mechanisms that may be
utilised by GBS. Whilst the currently characterised interactions
include the ability of the a adhesin to bind a1b1-integrin, BspC to
bind vimentin and the binding of BspA to gp340 (Bolduc & Madoff,
2007; Rego et al, 2016; Deng et al, 2019), our demonstration that the
b protein binds to CEACAM receptors identifies a novel type of inter-
action that potentially has important implications for pathogenesis. It
is unclear whether the different GBS adhesins operate independently
or in synergy with one another. Conceivably, they operate in synergy
with adhesins that bind ECM components, such as Srr1, Srr2, FsbA,
FsbB, FsbC, PilA or SfbA. As GBS can invade and survive within
epithelial cells (Patras et al, 2015), we speculate that CEACAM
engagement may also enhance virulence by promoting cellular inva-
sion, as reported for CEACAM-binding proteins of Gram-negative
pathogens (Billker et al, 2002; Korotkova et al, 2008; Tchoupa et al,
2015; Islam et al, 2018; Behrens et al, 2020). In addition, the possibil-
ity that binding to human CEACAMs mediated by b could modify
epithelial cell responses and promote translocation of virulence
factors, as described for H. pylori (K€oniger et al, 2016; Javaheri et al,
2016; Behrens et al, 2020), requires further investigation.
The capacity of individual pathogens to cause invasive systemic
infections is dependent on their capacity to evade and/or subvert
the host immune response. b protein interferes with antibody
opsonisation by binding IgA and disrupting interaction with FcaR
(Pleass et al, 2001) and interferes with complement opsonisation by
binding factor H, which acts as a cofactor in the degradation of C3b
(Areschoug et al, 2002b). Moreover, interactions with the inhibitory
receptors Siglec-5 and Siglec-7, which are expressed on leucocytes,
could enhance the immunosuppressive effects of b through induc-
tion of tyrosine phosphorylation (Carlin et al, 2009; Fong et al,
2018). As CEACAM1 is an inhibitory receptor, the binding of b
might also induce tyrosine phosphorylation and CEACAM1-depen-
dent immunosuppression, as been reported for Opa of Neisseria
spp., UspA1 of M. catarrhalis and HopQ of H. pylori (Boulton &
Gray-Owen, 2002; Slevogt et al, 2008; Javaheri et al, 2016; Gur et al,
2019). Thus, dual- or multi-engagement of b with different human
ligands may have potent immunosuppressive effects. However,
dissecting how b affects immune escape by interacting with different
ligands will be challenging, particularly because the CEACAM and
Siglec receptors have different cellular expression profiles. More-
over, the human specificity of the known ligand interactions
presents further challenges for characterising the function of b
protein in vivo. Nonetheless, the data collectively suggest that b
protein may act as a multitool protein that assists epithelial cell
adhesion, cellular invasion and immunosuppression. Whilst not all
strains of GBS express b, this protein is commonly expressed by
strains of serotypes Ia, Ib, II and V (Lindahl et al, 2005) and it has
been reported that expression of b at a high level is associated with
increased virulence (Nagano et al, 2006). It therefore seems likely
that b plays an important role in a large proportion of the serious
infections caused by GBS, through its ability to bind CEACAMs and
other human ligands.
In summary, our data demonstrate that an adhesin containing a
domain with unique Ig-like fold, the IgI3 fold, promotes binding of
GBS to human CEACAM1 and CEACAM5 receptors. Moreover,
homologous domains were identified in a variety of predicted
surface proteins from Gram-positive bacterial pathogens, suggesting
that many Gram-positive bacterial pathogens employ IgI3 domains
to engage human CEACAMs. Characterisation of these domains may
lead to a better understanding of pathogenicity mechanisms and
could pave the way for the development of novel therapeutic
approaches to prevent infections.
Materials and Methods
Bacterial growth conditions
Organisms used in this study are listed in Appendix Table S1. Bacte-
ria were cultured in Todd-Hewitt Broth (TH; S. agalactiae), TH
Broth + 1% yeast (S. pyogenes), Tryptic Soy Broth (TSB; S. aureus)
or Lysogeny Broth (LB; E. coli) and supplemented with antibiotics
as listed in Appendix Table S1.
Expression and purification of glycosylated and
unglycosylated rCEACAMs
Glycosylated CEACAMs were expressed and purified from Expi293F
cells (Life Technologies). In brief, gBlocks containing open reading
frames (ORFs) encoding the extracellular domain of CEACAMs, and
a C-terminal LPETGGS-6xHis tag, were cloned into the pcDNA3.4
expression vector (Invitrogen) (Appendix Table S2). Recombinant
CEACAM-His proteins were expressed in Expi293F cells (Life Tech-
nologies) cultured in Expi293 Expression Medium (Life Technolo-
gies) and purified by affinity chromatography (€AKTA Pure, GE
Healthcare Life Sciences) using a Nickel column (GE Healthcare Life
Sciences) as previously described (Zhao et al, 2020). Eluate was
dialysed against 300 mM NaCl 50 mM Tris pH 7.8 at 4°C. Unglyco-
sylated CEACAMs were expressed and purified from E. coli cultures.
In brief, gBlocks containing ORFs encoding the N-terminal or
A1B1A2 domains of CEACAM1, and a C-terminal LPETGGS-6xHis
tag, were cloned into the pRSET-C vector (Appendix Table S2).
Vectors were transformed into the Rosetta Gami (RG) E. coli strain.
RG strains were cultured in LB supplemented with 100 lg/ml ampi-
cillin and 1 mM D-glucose at 37°C overnight and subcultured 1:20
into LB supplemented with 1 mM D-glucose at 37°C until
OD600 = 0.4. Protein expression was induced by culturing for 4 h at
37°C following the addition of 1 mM IPTG. After lysis of bacteria,
proteins were purified using a Nickel column (GE Healthcare Life
Sciences) and affinity chromatography (€AKTA Pure, GE Healthcare
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Life Sciences). Eluates were dialysed against 300 mM NaCl 50 mM
Tris pH 7.8 at 4°C. Large-scale expression of tag-less CEACAM1-N
domain and point mutants for use in isothermal titration calorimetry
(ITC) and crystallisation were expressed using pET21d vectors in
E. coli and purified as previously described (Bonsor et al, 2015a).
Expression and purification of bacterial proteins
b, a and Rib proteins were purified from GBS cultures as previously
described (Lindahl et al, 1990; Stalhammar-Carlemalm et al, 1993).
Domains of the b proteins (B6N, IgABR, B6C, IgSF and b75KN)
and R28 (R28-IgI3) were cloned and expressed in E. coli
(Appendix Table S2). The IgSF domain structure was found to be in
a region overlapping the previously published B6C (amino acids
226–434) and b75KN domains (amino acids 434–788). (Areschoug
et al, 2002b; Lindahl et al, 2005) Therefore, we have updated
domain designations as follows: B6C represents amino acids 226–
390, IgSF represents amino acids 391–503 and b75KN represents
amino acids 504–788. Briefly, gBlocks containing ORFs and a C-
terminal LPETGGS-6xHis tag were cloned into the pRSET-C vector
using BamHI and NdeI. Vectors were transformed into the RG
strain. RG strains were cultured, induced, harvested and lysed as
described above for unglycosylated CEACAMs. Bacterial super-
natants were filtered, supplemented with 10 mM imidazole and
passed over a Nickel column (GE Healthcare Life Sciences). Proteins
were purified by affinity chromatography (€AKTA Pure, GE Health-
care Life Sciences), eluted with a gradient of imidazole (10–
500 mM) and were dialysed against 300 mM NaCl 50 mM Tris pH
7.8 at 4°C using 6–8 kDa dialysis tubing.
Binding of glycosylated and non-glycosylated recombinant
CEACAM to bacteria
6 × 106 of mid-logarithmic phase bacteria were incubated with
rCEACAM (1, 3, 5, 6 or 8), rCEACAM1-N or rCEACAM1-A1B1A2 at
4°C for 1 h with shaking. After washing in PBS + 0.1% bovine serum
albumin (BSA), rCEACAM on the bacterial surface was detected by
incubation with FITC-conjugated anti-HIS monoclonal antibody
(mAb) at 4°C for 1 h with shaking. Bacterial fluorescence was
measured by flow cytometric analysis following washing and fixation
in 1% paraformaldehyde (PFA). To detect rCEACAM binding to GBS
using pull-down Western blot analysis, bacterial pellets were resus-
pended in 1× sample buffer and heated to 95°C for 10 min. Lysates
were separated by SDS-PAGE in a 12.5% polyacrylamide gel at 270V,
blotted onto nitrocellulose membranes, blocked with 5% milk solu-
tion and probed with anti-CEACAM1 (clone C51X/8) mAb (BB
Singer, Essen, Germany). Membranes were probed using rabbit anti-
mouse-IgG-HRP and developed using ECL substrate.
Measurement of b protein expression by GBS strains
Rabbit antiserum was raised against b protein as previously
described (Lindahl et al, 1990). 6 × 106 of mid-logarithmic phase
bacteria were incubated with heat-inactivated 0.1% rabbit anti-b
serum or normal rabbit serum at 4°C for 1 h with shaking, washed
and incubated in the presence of PE-conjugated goat anti-rabbit-IgG
at 4°C for 1 h with shaking. Fluorescence of bacteria was measured
by flow cytometric analysis after washing and fixation in 1% PFA.
Detection of CEACAM1 and b protein interaction
Western blot analysis
Purified GBS proteins, or b protein domains (B6N, IgABR, B6C, IgSF
or b75KN), were separated by non-reducing SDS-PAGE, transferred
to nitrocellulose membranes, blocked with 5% milk solution over-
night at 4°C, probed with 10 lg/ml rCEACAM1-His (4°C) and horse
radish peroxidase (HRP)-conjugated mouse anti-His-IgG and devel-
oped using Pierce ECL Western Blot Substrate Reagent (Thermo
Fisher Scientific).
Binding of bacterial proteins to CEACAM1-coated dynabeads
rCEACAM-His was attached to nickel dynabeads (DB; Dynabead
His-tag pull-down and isolation, Invitrogen) following standard
protocols. Presence of CEACAM1 was confirmed by incubating DB
in the presence of 5 lg/ml anti-CEACAM or isotype control mAb,
and detection with PE-conjugated goat anti-mouse-IgG mAb. To
detect binding of purified GBS proteins, 40 lg of DB was incu-
bated in the presence of 10 lg/ml of b protein and probed with
0.1% mouse antiserum or normal mouse serum, and secondary
goat anti-mouse-IgG-PE mAb. Biotinylated proteins (including b-
IgSF-biotin or HSA-biotin amongst others) were incubated with
PE-conjugated Streptavidin on ice for 10 min. This generates
biotin–streptavidin complexes on the remaining 3 binding pockets
of streptavidin. To detect binding of proteins coupled with strepta-
vidin (b-IgSF-biotin or HSA-biotin formed with Streptavidin-PE),
20 lg of DB was incubated with varying concentrations of
protein–streptavidin. All dilutions and DB washes employed
PBS + 0.1% BSA, all incubations were performed for 1 h at 4°C,
and all fixations used 1% PFA. Fluorescence of DB was measured
by flow cytometry. For inhibition experiments, CEACAM-coated
DB were pre-incubated with 5 lg/ml anti-CEACAM1-N (clone
CC1/3/5-Sab, LeukoCom, Essen, Germany), anti-CEACAM1-A1B1
mAb (clone B3-17, BB Singer, Essen, Germany) or 10 lg/mL
rHopQ for 1 h at 4°C.
Binding of CEACAM to bacterial protein coated dynabeads
Proteins with C-terminal biotin tags were attached to strepta-
vidin-coated dynabeads (Dynabead M-280 Streptavidin, Invitro-
gen) following standard procedures. To detect binding of
rCEACAM-His or rCEACAM-N-His, 3 × 105 DB was incubated in
the presence of 9 ll of proteins (concentrations range 0.1–
30 lg/ml) and probed with FITC-conjugated mouse anti-His-IgG.
In the case of rSiglec-5-Fc, binding was detected using anti-IgG-
AF488. All dilutions and DB washes employed PBS + 0.1%
BSA, all incubations were performed for 1 h at 4°C, and all fix-
ations used 1% PFA. Fluorescence of DB was measured by
flow cytometry.
Isothermal titration calorimetry
Duplicate ITC measurements were performed on an iTC200 instru-
ment (GE Healthcare). Typically, 500 µM of unglycosylated
CEACAM-N domains were loaded into the syringe of the calorimeter
and 50 µM b-IgC2 protein was loaded into the syringe. All measure-
ments were performed at 25°C, with a stirring speed of 750 rpm, in
30 mM Tris-HCl, 150 mM NaCl, pH 7.5. Data were analysed using
the Origin 7.0 software.
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Adhesion of GBS to epithelial cells
HeLa and Chinese Hamster Ovary (CHO) cell lines expressing
CEACAMs were cultured as previously described (Daniel et al,
1993; Bos et al, 1998; Hollandsworth et al, 2020). Cells were
seeded into 24-well tissue culture plates. Tightly confluent mono-
layers were infected with mid-logarithmic phase (absorbance at
OD600 = 0.4) GBS strains at a multiplicity of infection (MOI) of 10.
Assays were commenced by centrifugation for 2 min at 700 rpm
and incubated at 37°C with 5% CO2 for 30 min. Cells were washed
five times with DMEM, detached with 0.25% trypsin and lysed
(PBS + 0.025% Triton-X). Adherent bacteria were enumerated
using serial dilution plating and growth on Todd-Hewitt agar
plates. In specific assays, cells were pre-incubated with 5 lg/ml
mAb (anti-CEACAM1-N or anti-CEACAM1-A1B1A2 mAb) for
60 min, or bacteria were pre-incubated with rCEACAM1-N for
60 min before co-culture. For confocal microscopy, experiments
were performed with FITC-labelled GBS at a MOI of 10 for 30 min.
After washing five times with PBS, monolayers were fixed with
4% PFA overnight prior to staining of nuclei with DaPI (Sigma
Aldrich) and cell membranes with AF647-conjugated wheat germ
agglutinin (Thermo Fisher Scientific). To perform assays with
detached CHO cell lines, adherent monolayers were detached by
incubation at 37°C for 5 min with Accutase Cell Detachment Solu-
tion (BioLegend). After washing, cells were resuspended to
3 × 106 cells/ml in DMEM containing 10% FCS. To measure
CEACAM expression, cells were incubated with mouse mAb clone
CC1/3/5-Sab (detects N-terminal domain of human CC1, CC3 and
CC5) for 30 min, washed and incubated with PE-conjugated rabbit
anti-mouse-IgG. To measure GBS binding, cells were incubated
with FITC-labelled GBS at a MOI of 10 for 30 min at 4°C. After
washing with PBS, cells were fixed in 4% PFA and fluorescence
was measured by flow cytometry.
An overview of all cell lines used in this study is provided in
Appendix Table S7. An overview of all antibodies used in this study
is provided in Appendix Table S8.
Crystallography of unglycosylated CEACAM1-N and b-IgSF
Initially, the b-IgSF and CEACAM1-N complex was prepared by
mixing the proteins with a slight excess of CEACAM1-N (1:1.1
ratio). Protein was concentrated using an amicon Ultra-4 10,000
NMWL before purification by size exclusion chromatography using
a Superdex 200 column (GE Healthcare) equilibrated with 20 mM
Tris, 150 mM NaCl, pH 7.5. The complex was concentrated to
9 mg/ml and screened against the commercial Wizards I/II/III/IV
(Rigaku) and JCSG+ (QIAgen) screens using a Crystal Gryphon
Protein Crystallography System (Art Robbins Instruments). Crystals
were found in several conditions but diffraction was never found
beyond 8.0 A in the best condition of 1.8 M Ammonium Sulphate
and 0.1 M Sodium Citrate pH 5.5. b-IgSF contains both a C-terminal
Sortase and 6xHis tag. This was removed by first incubating b-IgSF
by itself with Carboxypeptidase A (Sigma). 2 ml of 6 mg/ml of b-
IgSF was incubated with 1:100 w/w of Carboxypeptidase A for 24 h
at 4°C before the addition of another 1:100 w/w of Carboxypepti-
dase A and incubation for 24 h at room temperature. The reaction
was terminated by the addition of EDTA to a final concentration of
5 mM. The protein was concentrated using an Amicon Ultra-4
10,000 NMWL before purification by size exclusion chromatography
using a Superdex 200 column (GE Healthcare) equilibrated with
20 mM Tris, 150 mM NaCl, pH 7.5. CEACAM1-N was added in a
slight excess (1:1.05 ratio) and purified by size exclusion as
described above. The complex was concentrated and screened again
at a concentration of 7.5 mg/ml. Crystals again formed in the condi-
tion of 1.8 M Ammonium Sulphate and 0.1 M Sodium Citrate pH
5.5; however, their morphology was different. Crystals were cyro-
protected in 30 % v/v glycerol. A dataset was collected at beamline
12-2 at the Stanford Synchrotron Radiation Lightsource. Data were
processed, merged, scaled and converted to structure factors using
Aimless. Matthew’s coefficient suggests five complexes in the asym-
metric unit. Molecular replacement using MOLREP and CEACAM1-
N (PDB entry 2gk2) as a search model in MOLREP only found two
CEACAM1 molecules. Two copies of the complex would suggest a
high solvent content (78 %). Refinement using REFMAC5 and visu-
alisation in Coot showed that CEACAM1-N was well-placed and
residual electron density was present for the b-IgI3 protein. Density
modification was performed using Parrot (solvent flattening, histo-
gram matching and NCS averaging) to improve the maps. The b-
IgSF backbone was built manually. A PDBeFold search of the back-
bone showed that it was an IgI-like fold, with the closest fold by
R.M.S.D being the IgC2 domain of Perlecan (PDB entry 1gl4). The Ig
fold of b-IgSF possesses a previous unrecognised modification
(Fig 5B and C). We denote this as the I3-set domain and the domain
within b protein as b-IgI3. This was used to successfully position
sidechains, lock the registry and provide extra restraints during
refinement in REFMAC5 with ProSMART. The (b-IgI3)-(CEACAM1-
N) complex has been deposited to the PDB with the entry code,
6V3P. Atom contacts in the (b-IgI3)-(CEACAM1-N) complex inter-
face were identified using NCONT (CCP4) with a cut-off of 4.0 A
(Winn et al, 2011).
Bioinformatics analysis
BLAST analysis of the b-IgI3 amino acid sequence was performed to
identify homologs in bacterial proteins and subsequently aligned using
ClustalW. Phylogenetic analysis was performed using maximum likeli-
hood approach and 1,000 bootstrap replications in MEGA (Kumar
et al, 2016), and the resulting tree displayed with interactive tree of life
version 4 (Letunic & Bork, 2019). The structure of IgI3 homologs was
predicted using the b-IgI3 structure as input in SWISS-MODEL (Webb
& Sali, 2016). Only models passing a QMEAN score of < 4.00 were
further analysed. Docking of b-IgI3 structure or the R28-IgI3 predicted
structure to CEACAM1-N was simulated 50 times using ZDOCK server
(Pierce et al, 2014), in which CEACAM1-N residues F29, Q44, Q89, I91
and N95 were included as contact sites. The free energy contribution
of each simulation was interpedently calculated using MM/GBSA anal-
ysis on the HAWKDOCK server (Weng et al, 2019).
Data availability
The datasets produced in this study are available in the following
databases:
• Protein interaction (b-IgI3)-(CEACAM1-N) data: PDB 6V3P
(https://www.rcsb.org/structure/unreleased/6V3P).
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• The raw diffraction data have been deposited to the Integrated
Resource for Reproducibility in Macromolecular Crystallography
(https://proteindiffraction.org/).
All other data supporting the findings of this study are available
within the paper and its supplementary information files and are
available from the corresponding author on reasonable request.
Expanded View for this article is available online.
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